tp

TP-353 (EOS-61973) is a CDK7 inhibitor.

TP808 is a highly versatile intermediate for the construction of a wide range of tetracycline antibiotics.

TP-2857 (TAP2857) is a potent antimicrobial agent.

TGFβRI-IN-2 is a selective, potent and orally active inhibitor of (Activin-Like Kinase 5) ALK 5(pIC50 and pEC50 values of 7.6 and 6.63, respectively).

TP-004 is a potent, reversible inhibitor of methionine aminopeptidase 2 (MetAP2) with an IC50 of 6 nM.

TP-10 is a selective inhibitor of PDE10A against other PDEs with IC50 of 0.8 nM.

TP-472 is a selective inhibitor of BRD9 (Kd: 33 nM).

TP3011 is a potent topoisomerase I inhibitor equipotent as SN38 and is an active metabolite of CH-0793076.

TP003 is a novel non-selective GABAA receptor benzodiazepine site agonist with affinity for α1β2gam2, α2β3gam2, α3β3gam2, α5β2gam2, EC50 of 20.3, 10.6, 3.24, 5.64 nM, respectively. TP003 has antianxiety and partial anticonvulsant activity via the α2GABAA receptor.

TP-0427736 is a novel potent and selective ALK5 inhibitor (IC50: 2.72 nM). P0427736 was 300-fold higher than the inhibitory effect on ALK3. TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates the anagen phase i

TP-064 is a potent and selective PRMT4 inhibitor, featuring an IC50 < 10nM for methylation of H3 (1-25) and over 100-fold selectivity compared to other histone methyltransferases and non-epigenetic targets. It inhibits the methylation of MED12 in cells with an IC50 of 43 nM.

TP-271, a tetracyclines antibiotic, is used potentially for the treatment of community-acquired bacterial pneumonia (CABP).

TP-680 is a antagonist of cholecystokininA receptor.

TP-238, a potent and selective dual CECR2/BPTF probe, exhibits IC50 values of 30 nM and 350 nM, respectively. Additionally, it inhibits BRD9 with a pIC50 of 5.9, demonstrating lesser activity against another 338 kinases [1] [2].

EFdA-TP tetraammonium is an influential nucleoside reverse transcriptase (RT) inhibitor that effectively prevents RT-mediated DNA synthesis by acting as an immediate or delayed chain terminator (ICT or DCT). Additionally, EFdA-TP tetraammonium exhibits multiple mechanisms of inhibiting HIV-1 RT[1].

TP-472N serves as a negative control probe for TP-472, which is a specific and effective BRD7/9 probe.

TP-238 hydrochloride is a highly potent and selective dual CECR2/BPTF probe, demonstrating IC50 values of 30 nM and 350 nM, respectively. It additionally exerts inhibitory effects on BRD9, with a pIC50 value of 5.9, while displaying lower activity against 338 other kinases.

TP0586352 is a potent inhibitor of LpxC, exhibiting efficacy against carbapenem-resistant strains of Klebsiella pneumoniae without inducing cardiovascular risks.

FNC-TP, the intracellular active form of FNC, is a potent nucleoside reverse transcriptase inhibitor (NRTI) with broad-spectrum antiviral activity against HIV, HBV, and HCV.

EFdA-TP, a highly potent nucleoside reverse transcriptase (RT) inhibitor, exerts its inhibitory effect on RT-catalyzed DNA synthesis through both immediate and delayed chain termination mechanisms, commonly referred to as ICT and DCT, respectively. Additionally, EFdA-TP demonstrates its efficacy in inhibiting HIV-1 RT through multiple pathways.

TP-3654, a second-generation Pim kinase inhibitor (Ki values against Pim-1/3: 5/42 nM).

TP-0463518 is a highly potent HIF prolyl hydroxylase (PHD) inhibitor (IC50s: 13 nM and 18 nM for human and rat PHD2, respectively).

TP0427736 hydrochloride is a novel and selective ALK5 inhibitor with an IC50 of 2.72 nM, capable of inhibiting Smad2/3 phosphorylation in A549 cells, reducing TGF-β-induced growth inhibition of human root sheath cells, and prolonging the anagen phase of mouse hair follicles.

TP0438836 is a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor for the treatment of type 2 diabetes. TP0438836 showed IC50 values 28nM and 7 nM for hSGLT1 and hSGLT2 resepctively.